Pay in 4 interest-free payments of $5.00 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
If you are looking specifically for semaglutide dosing at weight loss levels (1.7 mg or 2.4 mg), you may need to call ahead to confirm availability
Sreerama, N
GIP Receptor Adipose Obesity Rev 2021 View on PubMed 2022 Journal of Hepatology NAFLD GLP-3 (Triple Agonist) Reduces Visceral Adiposity and Liver Steatosis Synergistically Finding: In high-fat diet obese rodent models, a GLP-1/GIP/glucagon triple agonist reduced visceral adipose tissue by 35% (vs 18% GLP-1 alone) and hepatic lipid content by 51% (vs 28% GLP-1 alone)
[PMID: 14585727] PubMed record related to this compound for laboratory literature review
US$ 24.25
US$ 23.58
US$ 26.41
US$ 25.19
US$ 21.86
US$ 22.52
US$ 29.65
US$ 25.09
US$ 20.81
